<DOC>
	<DOC>NCT01693692</DOC>
	<brief_summary>The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.</brief_summary>
	<brief_title>Phase 2 Study of TD-9855 to Treat Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<criteria>• American College of Rheumatology (ACR) Diagnostic Criteria for Fibromyalgia (FM) Informed consent 18 to 65 years of age Discontinue therapy with adrenergicacting drugs, and certain other medications Only acetaminophen or NSAID as rescue pain medication No narcotic pain meds or benzodiazepines Only nonbenzodiazepines as rescue hypnotics Any current psychiatric disorder, lifetime bipolar disorder, severe comorbid Axis II disorder, mental retardation, etc, as assessed by Mini International Neuropsychiatric Interview (MINI) Major depression at screening by MINI when unable to be washed out of MDD meds (investigator or provider's judgment) Risk of suicide (investigator opinion and/or CSSRS) Recent history of substance or alcohol abuse BMI &lt;18 or ≥45 Concurrent disease; pain for diagnosed illness other than FM; noncompliance; history of seizures; pheochromocytoma; glaucoma; CV disease; orthostatic hypotension or orthostatic tachycardia; untreated sleep apnea Abnormal lab values (liver, kidney, thyroid, and others)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Fibromyalgia</keyword>
</DOC>